Lung function trajectories in patients with idiopathic pulmonary fibrosis

被引:7
|
作者
Neely, Megan L. [1 ,2 ]
Hellkamp, Anne S. [1 ,2 ]
Bender, Shaun [3 ]
Todd, Jamie L. [1 ,2 ]
Liesching, Timothy [4 ]
Luckhardt, Tracy R. [5 ]
Oldham, Justin M. [6 ]
Raj, Rishi [7 ]
White, Eric S. [3 ]
Palmer, Scott M. [1 ,2 ]
机构
[1] Duke Clin Res Inst, Durham, NC 27701 USA
[2] Duke Univ, Med Ctr, Durham, NC 27710 USA
[3] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT USA
[4] Lahey Hosp & Med Ctr, Burlington, MA USA
[5] Univ Alabama Birmingham, Dept Med, Birmingham, AL USA
[6] Univ Michigan, Div Pulm & Crit Care Med, Ann Arbor, MI USA
[7] Stanford Univ, Sch Med, Stanford, CA USA
关键词
Interstitial lung disease; Lung function testing; Forced vital capacity; FORCED VITAL CAPACITY; CLINICAL-COURSE; INTERSTITIAL PNEUMONIA; SURVIVAL; PROGRESSION; MORTALITY; PIRFENIDONE; SPIROMETRY; NINTEDANIB; EFFICACY;
D O I
10.1186/s12931-023-02503-5
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing interstitial lung disease characterised by decline in lung function. We evaluated trajectories of forced vital capacity (FVC) and diffusing capacity (DLco) in a cohort of patients with IPF.Methods Patients with IPF that was diagnosed or confirmed at the enrolling centre in the previous 6 months were enrolled into the IPF-PRO Registry between June 2014 and October 2018. Patients were followed prospectively, with lung function data collected as part of routine clinical care. Mean trajectories of FVC and DLco % predicted in all patients and in subgroups by characteristics assessed at enrolment were estimated using a joint model that accounted for factors such as disease severity and visit patterns. Results Of 1002 patients in the registry, 941 had = 1 FVC and/or DLco measurement after enrolment. The median (Q1, Q3) follow-up period was 35.1 (18.9, 47.2) months. Overall, mean estimated declines in FVC and DLco % predicted were 2.8% and 2.9% per year, respectively. There was no evidence that the mean trajectories of FVC or DLco had a non-linear relationship with time at the population level. Patients who were male, white, had a family history of ILD, were using oxygen, or had prior/current use of antifibrotic therapy at enrolment had greater rates of decline in FVC % predicted. Patients who were male or white had greater rates of decline in DLco % predicted.Conclusions Data from the IPF-PRO Registry suggest a constant rate of decline in lung function over a prolonged period, supporting the inexorably progressive nature of IPF. A graphical abstract summarising the data in this manuscript is available at: https://www.usscicomms.com/respiratory/IPF-PRORegistry_LungFunctionTrajectories.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Autoantibody Status Is Not Associated With Change In Lung Function Or Survival In Patients With Idiopathic Pulmonary Fibrosis
    Goobie, G. C.
    Ford-Sahibzada, C.
    Fritzler, M.
    Johannson, K. A.
    Fell, C. D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [32] Autoantibody status is not associated with change in lung function or survival in patients with idiopathic pulmonary fibrosis
    Goobie, Gillian C.
    Ford-Sahibzada, Chelsea A.
    Fritzler, Marvin J.
    Johannson, Kerri A.
    Fell, Charlene D.
    RESPIRATORY MEDICINE, 2019, 153 : 85 - 90
  • [33] Gastroesophageal Reflux and Esophageal Motility in Patients With Idiopathic Pulmonary Fibrosis and Their Effect on Lung Function
    Laratta, Cheryl
    Kapasi, Ali
    Kalluri, Meena
    Lazarescu, Adriana
    GASTROENTEROLOGY, 2015, 148 (04) : S67 - S67
  • [34] Antidepressants and Idiopathic Pulmonary Fibrosis: Prevalence and Association with Lung Function
    Doeing, D. C.
    Patel, S.
    Takahashi, S.
    Thavarajagh, K.
    Noth, I.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 179
  • [35] PIRFENIDONE IS EFFICACIOUS IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) WITH MORE PRESERVED LUNG FUNCTION
    Noble, P. W.
    Bradford, W. Z.
    Costabel, U.
    Glaspole, I.
    Glassberg, M. K.
    Gorina, E.
    Kardatzke, D.
    Lancaster, L.
    Lederer, D. J.
    Nathan, S. D.
    Pereira, C.
    Spirig, D.
    Swigris, J. J.
    Valeyre, D.
    Albera, C.
    THORAX, 2015, 70 : A81 - A81
  • [36] Results of Lung Transplantation in Idiopathic Pulmonary Fibrosis Patients
    Algar, F. J.
    Espinosa, D.
    Moreno, P.
    Illana, J.
    Cerezo, F.
    Alvarez, A.
    Baamonde, C.
    Redel, J.
    Vaquero, J. M.
    Santos, F.
    Salvatierra, A.
    TRANSPLANTATION PROCEEDINGS, 2010, 42 (08) : 3211 - 3213
  • [37] A disease progression model of longitudinal lung function decline in idiopathic pulmonary fibrosis patients
    Bi, Youwei
    Rekic, Dinko
    Paterniti, Miya O.
    Chen, Jianmeng
    Marathe, Anshu
    Chowdhury, Badrul A.
    Karimi-Shah, Banu A.
    Wang, Yaning
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2021, 48 (01) : 55 - 67
  • [38] TIMING OF LUNG TRANSPLANT IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS
    Snyder, Laurie
    Palmer, Scott
    Neely, Megan
    Yow, Eric
    Bender, Shaun
    Flaherty, Kevin
    Leonard, Thomas
    Conoscenti, Craig
    CHEST, 2018, 154 (04) : 447A - 447A
  • [39] THE INFLUENCE OF CIGARETTE-SMOKING ON LUNG-FUNCTION IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS
    SCHWARTZ, DA
    MERCHANT, RK
    HELMERS, RA
    GILBERT, SR
    DAYTON, CS
    HUNNINGHAKE, GW
    AMERICAN REVIEW OF RESPIRATORY DISEASE, 1991, 144 (03): : 504 - 506
  • [40] A disease progression model of longitudinal lung function decline in idiopathic pulmonary fibrosis patients
    Youwei Bi
    Dinko Rekić
    Miya O. Paterniti
    Jianmeng Chen
    Anshu Marathe
    Badrul A. Chowdhury
    Banu A. Karimi-Shah
    Yaning Wang
    Journal of Pharmacokinetics and Pharmacodynamics, 2021, 48 : 55 - 67